Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Corinne Johnson Analyst Performance

Vice President, Equity Research - SMID Biotechnology at The Goldman Sachs Group

Corinne Johnson is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 10 publicly traded companies. Over the past year, Corinne Johnson has issued 15 stock ratings, including buy, hold, and sell recommendations. While full access to Corinne Johnson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Corinne Johnson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
15 Last 0 Years
Buy Recommendations
66.67% 10 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%10 ratings
Hold20.0%3 ratings
Sell13.3%2 ratings

Out of 15 total stock ratings issued by Corinne Johnson at The Goldman Sachs Group, the majority (66.7%) have been Buy recommendations, followed by 20.0% Hold and 13.3% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
10 companies

Corinne Johnson, an analyst at The Goldman Sachs Group, currently covers 10 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
90.0%
Manufacturing
1 company
10.0%

Corinne Johnson of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies
70.0%
MED - DRUGS
2 companies
20.0%
PHARMACEUTICAL PREPARATIONS
1 company
10.0%

Corinne Johnson's Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
5/15/2026Upgrade$8.34$15.00Buy
Immunovant, Inc. stock logo
IMVT
Immunovant
4/15/2026Boost Price Target$26.55$32.00Neutral
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4/1/2026Boost Price Target$23.28$34.00Buy
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1/15/2026Boost Price Target$29.54$39.00Neutral
Immunovant, Inc. stock logo
IMVT
Immunovant
12/15/2025Boost Price Target$25.72$28.00Neutral
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
12/4/2025Initiated Coverage$33.94$18.00Sell
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
12/4/2025Initiated Coverage$31.97$18.00Sell
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
9/16/2025Boost Price Target$11.96$20.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
9/5/2025Boost Price Target$16.86$24.00Buy
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
7/10/2025Initiated Coverage$133.51$182.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
7/10/2025Initiated Coverage$89.00$97.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
7/10/2025Initiated Coverage$9.24$18.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
7/10/2025Upgrade$30.28$55.00Buy
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7/10/2025Upgrade$21.35$33.00Buy
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
7/10/2025Upgrade$7.37$10.00Buy